

Disclosure continued.

Alavi is receiving research support from La Roche-Posay, the Hidradenitis Suppurativa Foundation, and the National Institutes of Health; has received research support from the Canadian Dermatology Foundation (now terminated); is receiving honoraria for consulting or participation in advisory boards from AbbVie, Almirall, Avalo Therapeutics, Boehringer Ingelheim, Cantargia, Incyte, LEO Pharma, Navigator Medicines, Novartis, Sanofi, and UCB; was Principal Investigator in clinical trials for Boehringer Ingelheim and Processa Pharmaceuticals (with payments to their institution; now terminated); serves on a data monitoring board for InflaRx, Almirall, and Zura Bio; and is a board member of the Hidradenitis Suppurativa Foundation.

Armstrong has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, EPI Health, Incyte, LEO Pharma, UCB, Janssen, Lilly, Nimbus, Novartis, Ortho Dermatologics, Sun, Dermavant, Dermira, Sanofi, Regeneron, Pfizer, and Modmed.

Ehst has received fees/honoraria/royalties as an advisory board member, contributor, and/or consultant for AbbVie, Amgen, AnaptysBio, Arcutis Biotherapeutics, Dermavant Sciences, Eli Lilly, Incyte, Janssen Biotech, LEO Pharma, Navigator Medicines, Novartis, Ortho Dermatologics, Priovant, Regeneron, Sanofi-Genzyme, UCB, and Up-To-Date; received speaking fees from AbbVie, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Incyte, LEO Pharma, Novartis, National Psoriasis Foundation, Ortho Dermatologics, Regeneron, Sanofi-Genzyme, and UCB; received institutional funding as an investigator for AbbVie, Allakos, Alumis, Amgen, Apogee, Arcutis Biotherapeutics, Bristol Myers Squibb, Celldex, Concert Pharmaceuticals, Dermavant Sciences, DermBiont, Eli Lilly, Incyte, Janssen Biotech, Kymab, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, Takeda, UCB, and Ventyx Biosciences.

Kim is a co-founder of Alys Pharmaceuticals and Neurommune Therapeutics; and has been a consultant for AbbVie, Abrax Japan, Almirall, Alys Pharmaceuticals, Cara Therapeutics, Clexio Biosciences, Eli Lilly, Escient Pharmaceuticals, Evommune, Galderma, Neurommune Therapeutics, Novartis, Pfizer, RecensMedical, Regeneron Pharmaceuticals Inc., Sanofi, and Septerna.

Merola is a consultant and/or investigator for AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Janssen, LEO Pharma, Moonlake, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB.

Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials, sponsored by AbbVie, Aileens, Almirall, Amgen, Apogee, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Incyte, Janssen-Cilag, Kyowa Kirin, LEO Pharma, L'Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Nektar, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi, and UCB; with payments to the institution.